Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

VRTX : 241.31 (+1.57%)
FATE : 96.14 (-1.08%)
EDIT : 65.47 (-0.44%)
NTLA : 71.40 (-3.98%)
CRSP : 181.24 (-3.85%)
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters' Option to Purchase Additional Shares

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

WFC : 32.24 (+1.07%)
FATE : 96.14 (-1.08%)
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

VRTX : 241.31 (+1.57%)
FATE : 96.14 (-1.08%)
EDIT : 65.47 (-0.44%)
NTLA : 71.40 (-3.98%)
CRSP : 181.24 (-3.85%)
Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock?

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

FATE : 96.14 (-1.08%)
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

WFC : 32.24 (+1.07%)
FATE : 96.14 (-1.08%)
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

FATE : 96.14 (-1.08%)
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics

MRNA : 147.00 (+12.20%)
FATE : 96.14 (-1.08%)
RARE : 146.76 (+4.48%)
NTLA : 71.40 (-3.98%)
MRSN : 20.03 (+1.01%)
5 Biotech Stocks That Have Gained More Than 200% in 2020

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

MRNA : 147.00 (+12.20%)
FATE : 96.14 (-1.08%)
RARE : 146.76 (+4.48%)
NTLA : 71.40 (-3.98%)
MRSN : 20.03 (+1.01%)
FATE Surges More Than 152% in Three Months: Here's Why?

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

JNJ : 165.98 (+1.49%)
GILD : 68.16 (+1.82%)
NVS : 98.47 (+1.62%)
FATE : 96.14 (-1.08%)
5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

ALXN : 161.32 (+1.00%)
MRNA : 147.00 (+12.20%)
FOLD : 20.44 (-3.08%)
FATE : 96.14 (-1.08%)
RARE : 146.76 (+4.48%)
XLRN : 125.88 (+1.02%)
EDIT : 65.47 (-0.44%)
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News

Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.

BCRX : 9.16 (-0.54%)
AMGN : 257.10 (+1.42%)
VRTX : 241.31 (+1.57%)
CRIS : 10.27 (-6.30%)
FATE : 96.14 (-1.08%)
CRSP : 181.24 (-3.85%)
ENLV : 12.15 (+0.83%)
Fate Therapeutics (FATE) Looks Good: Stock Adds 9.4% in Session

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

FATE : 96.14 (-1.08%)
Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

JNJ : 165.98 (+1.49%)
GILD : 68.16 (+1.82%)
BMY : 64.83 (+0.42%)
FATE : 96.14 (-1.08%)
Thinking about buying stock in Pfizer, Moderna, Oncternal Therapeutics, Fate Therapeutics, or Atara Biotherapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ONCT, FATE, and ATRA.

ATRA : 19.32 (+4.77%)
FATE : 96.14 (-1.08%)
MRNA : 147.00 (+12.20%)
ONCT : 5.47 (-0.55%)
PFE : 37.28 (+2.00%)
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells

FATE : 96.14 (-1.08%)
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

FATE : 96.14 (-1.08%)
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that...

FATE : 96.14 (-1.08%)
Fate Therapeutics Announces Participation in Upcoming Investor Conferences

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its...

FATE : 96.14 (-1.08%)
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

FATE : 96.14 (-1.08%)
Fate Therapeutics: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Thursday reported a loss of $58.7 million in its third quarter.

FATE : 96.14 (-1.08%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar